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macrophages, 22.1 ± 2.3% of plasma cells, 62.5 ± 1.1% of lympho-
cytes and 3.1 ± 0.9% of PMN. Total amount of cells was 224.1
± 32.8 per 1 mm2 of tumor.
Lymphocytes in ovarian carcinomas do not form large clus-
ters; they are disposed among other lymphoid cells in the stroma
on the periphery of the tumor. Plasma cells have a classical mor-
phological structure and often locate in the stroma and on the
periphery of the tumor. Macrophages are an integral part of the
tumor infiltrate. In the tumor they become stretched and angular.
Macrophages usually have large dimensions, and they are located
in the stroma as well as in the parenchyma among the cancer
cells. Segmented leukocytes (presented in the vast majority by
neutrophils) are constantly found in the infiltrate of the stroma
and the parenchyma, most often they are found near or among
massive necrosis.
Analysis of TANs functional activity in comparison with the
peripheral blood neutrophils has shown that MPO activity
elevated and amounted 2.21 ± 0.43 MCC against 1.40 ± 0.07 MCC
in the peripheral blood neutrophils, the level of CP also increased
and amounted 1.51 ± 0.39 MCC against 0.83 ± 0.43 MCC. TANs
activity in NBT-test was not significantly different from that of
the peripheral blood neutrophils.
TANs compose the minor part of primary ovarian tumor infil-
trate. Indicators of aerobic and anaerobic bactericidal activity of
TANs significantly exceed that of the peripheral blood neutrophils
in patients with ovarian cancer.
This work was conducted in the framework of implementing
the state assignment of the Ministry of Education and Science
of the Russian Federation No. 1163 – Russia.
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Background: Lung cancers are characterized by the genetic
alterations that often affect a common group of oncogenic signal-
ing pathways. Identification of biologically significant genetic
alterations in lung cancer that lead to activation of oncogenes
and inactivation of tumor suppressor genes has the potential to
provide further therapeutic opportunities (Cooper, 2013). In this
context, it is important that molecular aberrations may act as
negative predictors of sensitivity to treatment. The discovery of
driver oncogenes, such as activating mutations in the epidermal
growth factor receptor gene (EGFR), has made personalized med-
icine for lung cancer a reality. Despite the high initial results,
NSCLC patients acquire resistance to tyrosine kinase inhibitors
in the worldwide. There are several findings suggesting that the
effect of tyrosine kinase inhibitors could be limited to patients
harboring KRAS mutation. To date, a limited information
regarding link of morphological portrait of adenocarcinomas with
bearing of simultaneously concurrent mutations of KRAS and
EGFR genes. The detection of concurrent gene mutation is usually
carried out in a mixture of tumor cells. We plan to analyze EGFR
and KRAS mutations in all clonal components (or morphological
structures) of NSCLC tumors isolated by laser microdissection.
So, we suggest that NSCLC clonal components might bear two
concurrent EGFR and KRASmutations simultaneously or different
clonal components might bear either EGFR or KRAS mutations.
The data obtained can predict resistance to EGFR-TKIs and affect
therapeutic decision making.
Materials and methods: The tumor samples were obtained
from archived formalin-fixed paraffin-embedded tissue blocks.
Paraffin was removed by xylene extraction, and the sample was
subsequently lysed by proteinase K. The region containing the
highest percentage of tumor cells (at least 50%) was dissected.
Microscopes Axio Scope A1 and Axio Star plus (Carl Zeiss, Ger-
many) was used to perform histological analysis. If necessary,
tumour cells were carefully selected and removed from the sam-
ples by laser microdissection using a P.A.L.M. microlaser instru-
ment (PALM AdhesiveCaps, P.A.L.M., Bernried, Germany). EGFR
(exon 19 deletion and 21 L858R) and KRAS (Gly12Cys, Gly12Ser,
Gly12Arg, Gly12Val, Gly12Asp, Gly12Ala, Gly13Asp) gene
amplification was based on RT-PCR on CFX96 Real-Time System
(Bio-Rad).
Results: A total of 115 patients with stage (IIIB–IV) of NSCLC
with EGFR-TKI- sensitive mutations were eligible for the analysis.
A rare coexistence of KRAS and EGFR mutations were observed in
3 patients (2.6%). The first sample was described as nonmucinous
solid adenocarcinoma and has deletion of 19 exon of EGFR gene
and G12C mutation of KRAS gene. The second sample was
described as mucinous lepidic adenocarcinoma and has deletion
of 19 exon of EGFR gene and G12D mutation of KRAS gene. The
third sample was described as mucinous adenocarcinoma with
solid and acinar monoclonal components and also has deletion
of 19 exon of EGFR gene and G12C mutation of KRAS gene. Of
all the samples, only one had two different monoclonal compo-
nents. Unfortunately, this sample was not available due to biopsy
and few numbers of cells for microdissection. Fiala et al. (2013)
reported that KRAS mutations were not only as a negative
prognostic factor and also as a biomarker predicting resistance
to EGFR-TKIs, especially G12C. Patient with nonmucinous solid
adenocarcinoma with deletion of 19 exon and G12C (EGFR and
KRAS genes, respectively) is unlikely to benefit from receiving
gefitinib or erlotinib.
Conclusion: The data obtained show that further studies are
required to improve personalized therapy for NSCLC patients.
The frequency and type of KRAS and EGFR mutations were first
assessed in NSCLC patients from West Siberia.
This work was supported by a Grant from the OPTEK Company
(No 122/2014/51/Nvs).
http://dx.doi.org/10.1016/j.ejcsup.2015.08.032
P68
Novel monoclonal antibodies to C-terminal end of transmembrane
prostate androgen-induced protein (TMEPAI) for evaluation of its role
in gastric cancer prognosis
18 EJC SUPPLEMENTS 13 (2015) 1–75
